Loading stock…

GSK plc (GSK) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

GSKGSK

Revenue FY25$43.7B

GROWTH RATING↗

WEAK20 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+7%6

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-36%2

EPS growth, FY27E+7%6

EPS growth, FY28E+5%5

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue grew 7%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Earnings are set to grow in step with sales (EPS about 5%/yr vs revenue 4%/yr). One year dips: EPS falls 36% next year.

WEAKNESSES

Growth is the weak spot here, trailing 80% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

GSKGSK

Total return Current91.8%

Price return Current18.8%

MOMENTUM RATING↗

AVERAGE40 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return-10%3

YTD return-2%5

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return+12%6

3-year return+44%5

5-year return+46%6

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+44% over three years and +46% over five), roughly average for the market.

It's up 12% over the past year, but 22% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-3%) and so far this year (-2%).

WEAKNESSES

The stock is underperforming over three months (-10%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the stock is underperforming over three months.

04Value

Are you paying a fair price for it?

Stop guessing on GSK. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

GSKGSK

Revenue FY25$43.7B

GROWTH RATING↗

WEAK20 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+7%6

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-36%2

EPS growth, FY27E+7%6

EPS growth, FY28E+5%5

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue grew 7%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Earnings are set to grow in step with sales (EPS about 5%/yr vs revenue 4%/yr). One year dips: EPS falls 36% next year.

WEAKNESSES

Growth is the weak spot here, trailing 80% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

GSKGSK

Total return Current91.8%

Price return Current18.8%

MOMENTUM RATING↗

AVERAGE40 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return-10%3

YTD return-2%5

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return+12%6

3-year return+44%5

5-year return+46%6

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+44% over three years and +46% over five), roughly average for the market.

It's up 12% over the past year, but 22% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-3%) and so far this year (-2%).

WEAKNESSES

The stock is underperforming over three months (-10%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the stock is underperforming over three months.

04Value

Are you paying a fair price for it?

Stop guessing on GSK. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

GSK plc

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on GSK. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on GSK. Get the full investment case.

Premium